Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

14 Sökresultat.
Relevans Bedömning Nya först Gamla först

Subcutaneous injections of GSK 716155 in healthy volunteers; Study ID: 105229 - Day 1

- 2018-11-06 - 1 Formulär, 8 Item-grupper, 32 Dataelement, 1 Språk
Item-grupper: Randomization; Numbers, 12-lead ECG, Electrocardiogram; Telemetry, Vital Signs, Capillary Blood Glucose measurement, Pharmacokinetic aspects; Blood, Experimental drug, Therapeutic procedure; Confirmation
Study ID: 105229 Clinical Study ID: GLP105229 Study Title: A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Subcutaneous injections of GSK 716155 in healthy volunteers; Study ID: 105229 - Day 8

- 2018-10-05 - 1 Formulär, 11 Item-grupper, 40 Dataelement, 1 Språk
Item-grupper: 12-lead ECG, Electrocardiogram; Telemetry, Vital Signs, Clinical Chemistry, Hematology finding, Urinalysis, Capillary Blood Glucose measurement, drug biological activity, Collection of blood specimen for laboratory procedure, Pharmacokinetic aspects; Blood, Experimental drug, Therapeutic procedure; Confirmation
Study ID: 105229 Clinical Study ID: GLP105229 Study Title: A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2

Efficacy of Formulation X and AVANDIA in Subjects with Type 2 Diabetes Mellitus 100723 - Additional Forms - Investigational Product

- 2018-02-08 - 1 Formulär, 1 Item-grupp, 9 Dataelement, 1 Språk
Item-grupp: Investigational Product
Study ID: 100723 Clinical Study ID: AXR100723 Study Title: A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of Formulation X and AVANDIA™ (8mg OD) in Subjects with Type 2 Diabetes Mellitus Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 4 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia; Avandia XR; Avandia XR,Rosiglitazone XR,Avandia; Rosiglitazone XR Study Indication: Diabetes Mellitus, Type 2 Documentation part: Additional Forms - Investigational Product

Throughout: Adverse Events [AE_1] NCT01117584

- 2016-12-31 - 1 Formulär, 3 Item-grupper, 39 Dataelement, 1 Språk
Item-grupper: General Information, Genital Infection, Hypoglycemia Event
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 1 Run-ln Medical History [MH 1] NCT01117584 - Visit 1 Run-In Medical History NCT01117584

- 2016-12-05 - 1 Formulär, 2 Item-grupper, 18 Dataelement, 1 Språk
Item-grupper: Elements of Medical History, General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

DM-ASP1941-1941-CL-0004 NCT01071850 - Visit 7, Visit 8 DM-ASP1941-1941-CL-0004 NCT01071850

- 2016-08-14 - 1 Formulär, 8 Item-grupper, 27 Dataelement, 1 Språk
Item-grupper: Date of Visit, Orthostatic Vital Signs, ECG: 12 Lead ECG 1, Weight, Waist and Hip Circumference, Pregnancy Test, Meal Data, Blood Sample
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes MellitusTEST Study Visit 7, Visit 8

Visit 2 Baseline ADDQoL [QS_2] NCT01117584

- 2016-12-12 - 1 Formulär, 1 Item-grupp, 45 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Visit 2 Baseline ADDQoL [QS_2] NCT01117584

- 2016-12-12 - 1 Formulär, 1 Item-grupp, 45 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Throughout: Metformin Intake [CM_3] NCT01117584

- 2017-02-04 - 1 Formulär, 1 Item-grupp, 7 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Unscheduled Visit Study Drug: Accountability - Unscheduled [DA_1E] NCT01117584

- 2017-02-04 - 1 Formulär, 1 Item-grupp, 8 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Dose Study Drug: Accountability - Visit 5 / Kit 3 [DA_1C] NCT01117584

- 2017-02-04 - 1 Formulär, 1 Item-grupp, 7 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Dose Study Drug: Accountability - Visit 6 / Kit 4 [DA_1D] NCT01117584

- 2017-02-04 - 1 Formulär, 1 Item-grupp, 7 Dataelement, 1 Språk
Item-grupp: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial